Last but not least, the optimization of combination therapies using STAT3/5 inhibitors with molecules targeting tyrosine kinases or other key players in cancer will be required for finding the right combination that safely unlocks drug resistance in hematologic cancers. This evidence concerns the gene STAT3 and hematopoietic and lymphoid cell neoplasm.